LivaNova - Page title

LivaNova Reports Fourth Quarter and Full-Year 2016 Results

Mar 1, 2017

London, March 1, 2017 – LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced that, on 1 March 2017, LivaNova filed with the U.S. Securities and Exchange Commission its Current Report on Form 8-K, a copy of which can be found at www.sec.gov.

A copy of the Form 8-K is being submitted to the UK Listing Authority via the National Storage Mechanism and will shortly be available for inspection at http://www.morningstar.co.uk/uk/nsm.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs approximately 4,600 employees.

LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.

For more information, please visit www.livanova.com or contact:
Catherine Moroz
Company Secretary
Phone: +44 (0) 203 325 0662
e-mail: company.secretariat@livanova.com

Karen King
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Email: corporate.communications@livanova.com